Skip to main content

Edesa Biotech Inc (EDSA) Stock

Edesa Biotech Inc Stock Details, Movements and Public Alerts

Stock Details

Edesa Biotech Inc (EDSA), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $5.12. Over the past 52 weeks, it has ranged between $0.72 and $8.74. This places the current price at 58.6% of its 52-week high and 611.1% above its 52-week low. Recent trading volume was recorded at 793,576. The 14-day Relative Strength Index (RSI) stands at 76.08, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $1.35 by 279.26%. Similarly, it is above its 200-day moving average of $1.95 by 162.56%. The MACD histogram is 0.15, indicating bullish momentum (MACD Line: 0.13, Signal Line: -0.02).

52-Week Range

$8.74 - $0.72

-41.42% from high · +611.11% from low

Avg Daily Volume

8,321,221

20-day average

100-day avg: 1,875,275

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

0.17

Price to Book

10.68

EV/EBITDA

-1.25

EPS (TTM)

-$1.07

Price to Sales

120477.93

Beta

0.05

Less volatile than market

Q:How is EDSA valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is EDSA's risk profile compared to the market?
With a beta of 0.05, Edesa Biotech Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 10.68 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-8,252,636

Return on Equity

-96.40%

Return on Assets

-55.30%

Revenue Growth (YoY)

-99.90%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is EDSA's business model?
Profitability metrics are not available for this stock.
Q:What are EDSA's recent growth trends?
Edesa Biotech Inc's revenue declined by 99.90% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$49.8M

Revenue (TTM)

$500

Revenue/Share (TTM)

$0.00

Shares Outstanding

8.35M

Book Value/Share

$0.56

Asset Type

Common Stock

Q:What is EDSA's market capitalization and position?
Edesa Biotech Inc has a market capitalization of $49.8M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 8.35M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does EDSA's price compare to its book value?
Edesa Biotech Inc's book value per share is $0.56, while the current stock price is $5.12, resulting in a price-to-book (P/B) ratio of 9.16. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$11.00

114.84% upside potential

Analyst Recommendations

Strong Buy

0

Buy

2

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for EDSA?
2 analysts cover EDSA with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $11.00 implies 114.8% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on EDSA?
Current analyst recommendations:02 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 15, 2026, 02:46 AM

Technical Indicators

RSI (14-day)

76.08

Overbought

50-Day Moving Average

$1.35

279.26% above MA-50

200-Day Moving Average

$1.95

162.56% above MA-200

MACD Line

0.13

MACD Signal

-0.02

MACD Histogram

0.15

Bullish

Q:What does EDSA's RSI value tell investors?
The RSI (Relative Strength Index) for EDSA is currently 76.08, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret EDSA's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.13 above the signal line at -0.02, with histogram at 0.15. This bullish crossover suggests upward momentum is building. The 50-day MA ($1.35) is below the 200-day MA ($1.95), forming a death cross pattern that often warns of extended weakness. Price is currently above both MAs, confirming strength.

Indicators last updated: Mar 3, 2026, 12:51 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for EDSA and get notified when the price changes.

Stay Ahead of the Market with Edesa Biotech Inc Alerts

Set up price alerts for Edesa Biotech Inc and get notified instantly when the price hits your target. Never miss an important price movement again.